Literature DB >> 10223936

Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.

J A Johnson1, J D Gangemi.   

Abstract

(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) is a nucleoside phosphonate analog which in its active diphosphorylated form is known to inhibit herpesvirus DNA polymerase. In this study, we have demonstrated that, in a dose-dependent manner, this compound irreversibly suppressed proliferation of cells infected with human papillomavirus (HPV), which does not possess a viral DNA polymerase. To elucidate the mechanism of cell growth inhibition, cell cycle indicator-regulator expression, thymidine incorporation, transcript levels of apoptosis factors, and anabolic products of HPMPC following drug treatment were evaluated. HPMPC treatment reduced WAF1 (p21) levels independent of those of p53, while proliferating cell nuclear antigen increased. However, in comparison to controls, HPMPC-treated cells displayed a decrease in thymidine incorporation, indicating an inhibition of host DNA polymerase activity. In normal primary keratinocytes, HPMPC predominantly accumulated in the form of the choline adduct HPMPCp-choline. However, in HPV type 16-transformed keratinocytes, HPMPCpp was the most abundant anabolic product, with little HPMPCp-choline having formed. The data imply that an unrecognized viral factor is modulating the conversion of nucleotides, including HPMPC, to the triphosphorylated form.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223936      PMCID: PMC89133     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  STUDIES ON SYNCHRONOUS DIVISION OF TISSUE CULTURE CELLS INITIATED BY EXCESS THYMIDINE.

Authors:  D BOOTSMA; L BUDKE; O VOS
Journal:  Exp Cell Res       Date:  1964-01       Impact factor: 3.905

2.  Macromolecular synthesis in permeable liver cells.

Authors:  R H Hilderman; M P Deutscher
Journal:  Arch Biochem Biophys       Date:  1976-08       Impact factor: 4.013

3.  Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.

Authors:  L M De Castro; E R Kern; E De Clercq; A Ghaffar; E P Mayer; P E Vogt; J D Gangemi
Journal:  Antiviral Res       Date:  1991-07       Impact factor: 5.970

4.  Bioavailability and metabolism of cidofovir following topical administration to rabbits.

Authors:  K C Cundy; G Lynch; W A Lee
Journal:  Antiviral Res       Date:  1997-07       Impact factor: 5.970

5.  Synthesis of 2'-aminomethyl derivatives of N-(2-(phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents.

Authors:  H Dvoráková; M Masojídková; A Holý; J Balzarini; G Andrei; R Snoeck; E De Clercq
Journal:  J Med Chem       Date:  1996-08-16       Impact factor: 7.446

6.  Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation.

Authors:  X Xiong; J L Smith; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro.

Authors:  A Holý; I Votruba; A Merta; J Cerný; J Veselý; J Vlach; K Sedivá; I Rosenberg; M Otmar; H Hrebabecký
Journal:  Antiviral Res       Date:  1990-06       Impact factor: 5.970

8.  The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice.

Authors:  J Neyts; R Sadler; E De Clercq; N Raab-Traub; J S Pagano
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

9.  Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine].

Authors:  R Snoeck; W Wellens; C Desloovere; M Van Ranst; L Naesens; E De Clercq; L Feenstra
Journal:  J Med Virol       Date:  1998-03       Impact factor: 2.327

10.  Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types.

Authors:  A T Lorincz; R Reid; A B Jenson; M D Greenberg; W Lancaster; R J Kurman
Journal:  Obstet Gynecol       Date:  1992-03       Impact factor: 7.661

View more
  10 in total

1.  Antiproliferative effects of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine against Me-180 human cervical cancer cells in vitro and in vivo.

Authors:  Nadejda Valiaeva; Julissa Trahan; Kathy A Aldern; James R Beadle; Karl Y Hostetler
Journal:  Chemotherapy       Date:  2010-03-08       Impact factor: 2.544

2.  Topical therapies for the treatment of anal high-grade squamous intraepithelial lesions.

Authors:  Christina Megill; Timothy Wilkin
Journal:  Semin Colon Rectal Surg       Date:  2017-04-26

3.  The impact of cidofovir treatment on viral loads in adult recurrent respiratory papillomatosis.

Authors:  S Mikolajczak; G Quante; S Weissenborn; A Wafaisade; U Wieland; J C Lüers; J P Klussmann; D Beutner
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-06       Impact factor: 2.503

4.  Human Papillomavirus (HPV) Entry Inhibitors.

Authors:  Yun Zhu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Alpha interferon augments cidofovir's antiviral and antiproliferative activities.

Authors:  Jeffrey A Johnson; J David Gangemi
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

6.  Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients.

Authors:  Eric Deutsch; Christine Haie-Meder; Mohamed Amine Bayar; Michele Mondini; Mélanie Laporte; Renaud Mazeron; Julien Adam; Andrea Varga; Gilles Vassal; Nicolas Magné; Cyrus Chargari; Emilie Lanoy; Patricia Pautier; Antonin Levy; Jean-Charles Soria
Journal:  Oncotarget       Date:  2016-05-03

Review 7.  Advances in the Development of Antiviral Strategies against Parvovirus B19.

Authors:  Elisabetta Manaresi; Giorgio Gallinella
Journal:  Viruses       Date:  2019-07-18       Impact factor: 5.048

Review 8.  The Interaction of Human Papillomavirus Infection and Prostaglandin E2 Signaling in Carcinogenesis: A Focus on Cervical Cancer Therapeutics.

Authors:  Janice García-Quiroz; Bismarck Vázquez-Almazán; Rocío García-Becerra; Lorenza Díaz; Euclides Avila
Journal:  Cells       Date:  2022-08-15       Impact factor: 7.666

9.  Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage.

Authors:  Tim De Schutter; Graciela Andrei; Dimitri Topalis; Lieve Naesens; Robert Snoeck
Journal:  BMC Med Genomics       Date:  2013-05-23       Impact factor: 3.063

10.  Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms.

Authors:  Barbara Mertens; Tatiane Nogueira; Ruzena Stranska; Lieve Naesens; Graciela Andrei; Robert Snoeck
Journal:  Oncotarget       Date:  2016-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.